Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus | Zendy

James C. Yao | Zendy; Marianne Pavel | Zendy; Alexandria T. Phan | Zendy; Matthew H. Kulke | Zendy; Sakina Hoosen | Zendy; J. Peter | Zendy; Azzeddine Cherfi | Zendy; Kjell E. Öberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

Author(s) -

James C. Yao,

Marianne Pavel,

Alexandria T. Phan,

Matthew H. Kulke,

Sakina Hoosen,

J. Peter,

Azzeddine Cherfi,

Kjell E. Öberg

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-0666

Subject(s) - chromogranin a , enolase , everolimus , neuroendocrine tumors , context (archaeology) , medicine , immunohistochemistry , cancer research , oncology , biology , paleontology

Everolimus, an oral inhibitor of mammalian target of rapamycin, significantly prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (pNET). Chromogranin A (CgA) and neuron-specific enolase (NSE) are considered general biomarkers of these tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research